Research
Dr Toshner undertook a British Heart Foundation Research Training Fellowship in Cambridge in 2007 where he trained in cell and molecular mechanisms of endothelial dysfunction in pulmonary hypertension. He was appointed to a Wellcome/ NIHR Clinical Lecturer in 2010. He is currently a University Lecturer and his group is interested in translational and experimental research in pulmonary vascular diseases. He is currently the Chief-Investigator of the Transform-UK trial, the first investigator-led multicentre trial to involve all 7 specialist centres in the UK. He is leading an international genotyping/ phenotyping collaboration in chronic thromboembolic pulmonary hypertension and has close ties to the Pulmonary Vascular Diseases Unit in Royal Papworth Hospital. His research group is focused on preclinical target identification and early phase trials in pulmonary vascular diseases.
The major themes of the group are-
- Genetic susceptibility to pulmonary hypertension
- The pathobiology of chronic thromboembolic pulmonary hypertension
- Novel early phase drug development in pulmonary hypertension
Teaching
Dr Toshner is Director of the MPhil in Translational Biomedical Research and stem lead for all Clinical School taught MPhils.
Selected References
Hadinnapola C et al. Circulation. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. 2017 Nov 21;136(21):2022-2033. doi: 10.1161/CIRCULATIONAHA.117.028351. Epub 2017 Sep 28. PMID:28972005
Hernández-Sánchez J et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ. 2018 Jan-Mar;8(1):2045893217735820. doi: 10.1177/2045893217735820. Epub 2017 Sep 28. PMID: 28956500
Rhodes CJ et al. Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2017 Jan 31;135(5):460-475. doi: 10.1161/CIRCULATIONAHA.116.024602. Epub 2016 Nov 21. PMID: 27881557
Aldabbous L et al. Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2078-87. doi: 10.1161/ATVBAHA.116.307634. Epub 2016 Jul 28. PMID: 27470511
Cowburn AS et al. HIF2α-arginase axis is essential for the development of pulmonary hypertension. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8801-6. doi: 10.1073/pnas.1602978113. Epub 2016 Jul 18. PMID: 27432976
Cannon JE et al. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation. 2016 May 3;133(18):1761-71. doi: 10.1161/CIRCULATIONAHA.115.019470. Epub 2016 Apr 6. PMID: 27052413
Toshner M. Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances? Eur Respir J. 2016 Feb;47(2):388-9. doi: 10.1183/13993003.01858-2015. No abstract available. PMID: 26828050
Crosby A et al. Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1355-65. doi: 10.1164/rccm.201412-2262OC. PMID: 26308618
Soon E et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015 Oct 1;192(7):859-72. doi: 10.1164/rccm.201408-1509OC. PMID: 26073741
Hadinnapola C et al. The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease. Physiol Rep. 2015 Apr;3(4). pii: e12363. doi: 10.14814/phy2.12363. PMID: 25902784
Taboada D et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014 Dec;44(6):1635-45. doi: 10.1183/09031936.00050114. Epub 2014 Sep 18. PMID: 25234805
Toshner M et al. Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells. PLoS One. 2014 Mar 20;9(3):e91334. doi: 10.1371/journal.pone.0091334. eCollection 2014. PMID: 24651450
Dunmore BJ et al. The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet. 2013 Sep 15;22(18):3667-79. doi: 10.1093/hmg/ddt216. Epub 2013 May 12. PMID: 23669347